Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 16, 2016
Zacks Investment Research has downgraded Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) to Hold in a statement released on 10/11/2016.
On 08/16/2016, Zacks Investment Research released a statement for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) bumped up the target price from $0.00 to $9.75 that suggested an upside of 0.11%.
Boasting a price of $9.20, Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) traded -2.27% lower on the day. With the last stock price close up 18.96% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Foamix Pharmaceuticals Ltd has recorded a 50-day average of $9.41 and a two hundred day average of $7.61. Volume of trade was down over the average, with 73,954 shares of FOMX changing hands under the typical 188,026
With a total market value of $0, Foamix Pharmaceuticals Ltd has with a one year low of $5.48 and a one year high of $10.40 .
Brief Synopsis About Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations. The Company develops FMX101, FMX102, FMX103 and FDX104 using its technology, which includes foam-based platforms. The Company's lead product candidate FMX101, is a novel topical foam formulation of the antibiotic minocycline. The Company develops FMX102, a minocycline foam product candidate for the treatment of impetigo, including cases of impetigo caused by methicillin-resistant staphylococcus aureus (MRSA). It is also developing FMX103, minocycline foam for rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It completed a Phase II clinical trial for FMX102.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.